Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (41-50 of 917) with videos related to

Pageof 92
Sort By:
Urologie (Heidelberg, Germany)|February 8, 2024
[Local therapies for oligometastatic hormone-sensitive prostate cancer]Fabian Falkenbach, Thomas Steuber, Markus Graefen
Urology|November 11, 2019
AUTHOR REPLYSophie Knipper, Markus Graefen, Pierre I Karakiewicz
European Urology Oncology|April 11, 2025
Preventative Function-sparing Radical Prostatectomy: Experience in a Tertiary Referral CentreAlexander Haese, Markus Graefen, Aliaksandra Pott, et al.
European Urology|July 18, 2017
Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?Philipp Mandel, Markus Graefen, Hartwig Huland, et al.
European Urology|October 8, 2015
Detailed Quantification of High-grade Cancer Allows Precise Prediction of Prostate Cancer PrognosisMarkus Graefen, Thorsten Schlomm, Guido Sauter, et al.
Current Urology Reports|May 27, 2004
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancerAlexander Haese, Markus Graefen, Hartwig Huland, et al.
European Urology Focus|February 9, 2021
Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate CancerSophie Knipper, Lars Budäus, Markus Graefen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?Philipp Schriefer, Stefan Steurer, Hartwig Huland, et al.
BJU International|May 22, 2021
Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579)Sophie Knipper, Derya Tilki, Markus Graefen, et al.
Therapeutic Advances in Urology|October 5, 2011
Surgery for high-risk localized prostate cancerJan Schmitges, Quoc-Dien Trinh, Jochen Walz, et al.
Pageof 92

Showing results (41-50 of 917) with videos related to

Sort By:
Pageof 92
Urologie (Heidelberg, Germany)|February 8, 2024
[Local therapies for oligometastatic hormone-sensitive prostate cancer]Fabian Falkenbach, Thomas Steuber, Markus Graefen
Urology|November 11, 2019
AUTHOR REPLYSophie Knipper, Markus Graefen, Pierre I Karakiewicz
European Urology Oncology|April 11, 2025
Preventative Function-sparing Radical Prostatectomy: Experience in a Tertiary Referral CentreAlexander Haese, Markus Graefen, Aliaksandra Pott, et al.
European Urology|July 18, 2017
Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?Philipp Mandel, Markus Graefen, Hartwig Huland, et al.
European Urology|October 8, 2015
Detailed Quantification of High-grade Cancer Allows Precise Prediction of Prostate Cancer PrognosisMarkus Graefen, Thorsten Schlomm, Guido Sauter, et al.
Current Urology Reports|May 27, 2004
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancerAlexander Haese, Markus Graefen, Hartwig Huland, et al.
European Urology Focus|February 9, 2021
Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate CancerSophie Knipper, Lars Budäus, Markus Graefen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?Philipp Schriefer, Stefan Steurer, Hartwig Huland, et al.
BJU International|May 22, 2021
Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579)Sophie Knipper, Derya Tilki, Markus Graefen, et al.
Therapeutic Advances in Urology|October 5, 2011
Surgery for high-risk localized prostate cancerJan Schmitges, Quoc-Dien Trinh, Jochen Walz, et al.
Pageof 92